T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

Cited by (1,002)

Items 301–400 of 1,002

1. The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer
   Yanyan Tang, Ping Zhang, Yumin Wang, Jinpeng Wang, Min Su, Ying Wang, Lianqing Zhou, Jumei Zhou, Wei Xiong, Zhaoyang Zeng et al. · 2020 · Frontiers in Immunology
2. PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
   Sylvain Simon, Valentin Voillet, Virginie Vignard, Zhong Wu, Camille Dabrowski, Nicolas Jouand, Tiffany Beauvais, Amir Khammari, Cécile Braudeau, Régis Josien et al. · 2020 · Journal for ImmunoTherapy of Cancer
3. Immune Aging and Immunotherapy in Cancer
   Melanie Kaiser, Maria Donatella Semeraro, Markus Herrmann, Gudrun Absenger, Armin Gerger, Wilfried Renner · 2021 · International Journal of Molecular Sciences
4. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy
   Christopher Aled Chamberlain, Eric Bennett, Anders Handrup Kverneland, Inge Marie Svane, Marco Donia, Özcan Met · 2022 · Molecular Therapy — Oncolytics
5. Fatty acid binding protein 5 suppression attenuates obesity-induced hepatocellular carcinoma by promoting ferroptosis and intratumoral immune rewiring
   Jonathan Sun, Enric Esplugues, Alicia Bort, M. Cardelo, Inmaculada Ruz-Maldonado, Pablo Fernández-Tussy, C. Wong, Hehe Wang, I. Ojima, M. Kaczocha et al. · 2024 · Nature Metabolism
6. CD28 co-stimulation: novel insights and applications in cancer immunotherapy
   Michael T. Lotze, Scott H. Olejniczak, Dimitris Skokos · 2024 · Nature reviews. Immunology
7. Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity
   Lauren Zebertavage, Alejandro F. Alice, Marka R. Crittenden, Michael J. Gough · 2020 · Scientific Reports
8. Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development
   Yuli Wang, Xingyan Zhang, Yuyan Wang, Wenjing Zhao, Huling Li, Lixing Zhang, Xinping Li, Tiejun Zhang, Hongbing Zhang, He Huang et al. · 2021 · Acta Pharmaceutica Sinica B
9. Emerging Roles of Liquid–Liquid Phase Separation in Cancer: From Protein Aggregation to Immune-Associated Signaling
   Jiahua Lu, Junjie Qian, Zhentian Xu, Shengyong Yin, Lin Zhou, Shusen Zheng, Wu Zhang · 2021 · Frontiers in Cell and Developmental Biology
10. Multiplatform Single-Cell Analysis Identifies Immune Cell Types Enhanced in Pulmonary Fibrosis
    Ana Paula Moreira Serezani, Bruno D. Pascoalino, Júlia Miranda Ribeiro Bazzano, Katherine N. Vowell, Harikrishna Tanjore, Chase J. Taylor, Carla L. Calvi, A. Scott McCall, Matthew D. Bacchetta, Ciara M. Shaver et al. · 2022 · American Journal of Respiratory Cell and Molecular Biology
11. SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms
    Wang, Ye, Mohseni, Morvarid, Grauel, Angelo, Diez, Javier Estrada, Guan, Wei, Liang, Simon, Choi, Jiyoung Elizabeth, Pu, Minying, Chen, Dongshu, Laszewski, Tyler et al. · 2021 · Scientific Reports
12. IL-27 and TCR Stimulation Promote T Cell Expression of Multiple Inhibitory Receptors
    Jonathan Howard DeLong, Aisling O’Hara Hall, Matt Rausch, Devapregasan Moodley, Joseph A. Perry, Jeongho Park, Anthony T. Phan, Daniel P. Beiting, Ross M. Kedl, Jonathan A. Hill et al. · 2019 · ImmunoHorizons
13. The CAR T‐Cell Mechanoimmunology at a Glance
    Rui Li, Chao Ma, Haogang Cai, Weiqiang Chen · 2020 · Advanced Science
14. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cells
    Sergey N. Zolov, Skyler P. Rietberg, Challice Lee Bonifant · 2018 · Cytotherapy
15. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia
    Mansour Alfayez, Ghayas C. Issa, Keyur Pravinchandra Patel, Feng Wang, Xuemei Wang, Nicholas James Short, Jörge E. Cortes, Tapan Mahendra Kadia, Farhad Ravandi, Sherry A. Pierce et al. · 2020 · Leukemia
16. Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1 + PD-1 + CD8 T cells
    Étienne Humblin, Isabel Korpas, Jiahua Lu, Dan Filipescu, Verena van der Heide, Simon Goldstein, Abishek Balachandra Vaidya, Alessandra Soares Schanoski, Beatrice Casati, Myvizhi Esai Selvan et al. · 2023 · Science Immunology
17. Toxoplasma gondii: CD8 T Cells Cry for CD4 Help
    Imtiaz A. Khan, SuJin Hwang, Magali M. Moretto · 2019 · Frontiers in Cellular and Infection Microbiology
18. Extracellular vesicle PD‐L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies
    Liu, Jiaxing, Peng, Xueqiang, Yang, Shuo, Li, Xinyu, Huang, Mingyao, Wei, Shibo, Zhang, Sheng, He, Guangpeng, Zheng, Hongyu, Fan, Qing et al. · 2022 · Cell Communication and Signaling
19. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
    Daan P. Hurkmans, Edwin A. Basak, Nina Schepers, Esther Oomen‐de Hoop, Cor H. van der Leest, Samira El Bouazzaoui, Sander Bins, Stijn L.W. Koolen, Stefan Sleijfer, Astrid A.M. van der Veldt et al. · 2020 · Journal for ImmunoTherapy of Cancer
20. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence
    Daniel C. Kreatsoulas, Chelsea M. Bolyard, Bill Xingjun Wu, Hakan Çam, Pierre Giglio, Zihai Li · 2022 · Journal of Hematology & Oncology
21. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma
    W. Robert Liu, Margaret Ann Shipp · 2017 · Blood
22. Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects
    Kirsten E. Diggins, Elisavet Serti, VIRGINIA S. MUIR, Mario G. Rosasco, Tingting Lü, Elisa Balmas, Gerald T. Nepom, Sarah Alice Long, Peter S. Linsley · 2020 · JCI Insight
23. Icaritin inhibits PD‐L1 expression by Targeting Protein IκB Kinase α
    Dongliang Mo, Hai Zhu, Jun Wang, Haibang Hao, Yuming Guo, Jiaojiao Wang, Xu Han, Liangfeng Zou, Zhongwan Li, Hua Yao et al. · 2020 · European Journal of Immunology
24. FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis
    Manolo Sambucci, Francesca Gargano, Veronica De Rosa, Marco De Bardi, Mario Picozza, Roberta Placido, Serena Ruggieri, Alessia Capone, Claudio Gasperini, Giuseppe Matarese et al. · 2018 · Scientific Reports
25. Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
    Zhang, Chaoxu, Fan, Yibo, Che, Xiaofang, Zhang, Min, Li, Zhi, Li, Ce, Wang, Shuo, Wen, Ti, Hou, Kezuo, Shao, Xinye et al. · 2020 · Frontiers in Oncology
26. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy
    Sjoerd T. T. Schetters, Ernesto Rodríguez, Laura J. W. Kruijssen, Matheus H. W. Crommentuijn, Louis Boon, Jan Van den Bossche, Joke M. M. den Haan, Yvette van Kooyk · 2020 · Journal for ImmunoTherapy of Cancer
27. B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
    Zena N. Willsmore, R. J. C. Harris, Silvia Crescioli, Khuluud Hussein, Helen Kakkassery, Deepika Thapa, Anthony Cheung, Jitesh Chauhan, Heather J. Bax, Alicia M. Chenoweth et al. · 2021 · Frontiers in Immunology
28. Metabolic regulation of the cancer-immunity cycle
    Luis F. Somarribas Patterson, Santosha Adipudi Vardhana · 2021 · Trends in Immunology
29. Immune Checkpoint Receptors Signaling in T Cells
    Gianluca Baldanzi · 2022 · International Journal of Molecular Sciences
30. TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives
    Zhuohong Yan, Chunmao Wang, Jinghong Wu, Jinghui Wang, Teng Ma · 2025 · Molecular Biomedicine
31. Immune checkpoint inhibitors: new strategies to checkmate cancer
    Ruairí Wilson, Thomas R. Jeffry Evans, Alasdair R. Fraser, Robert J. B. Nibbs · 2017 · Clinical & Experimental Immunology
32. The PD-1:PD-L1 axis in Inflammatory Arthritis
    Mary Canavan, Achilleas Floudas, Douglas James Veale, Ursula Fearon · 2021 · BMC Rheumatology
33. Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099
    Xiaojun Sun, Y Ren, Steven Gunawan, Peng Teng, Zhengming Chen, HR Lawrence, Jianfeng Cai, Nicholas J. Lawrence, Jie Wu · 2018 · Leukemia
34. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation
    Chenghao Pan, Haiyan Yang, Yang Lu, Shengquan Hu, Yizhe Wu, Qiaojun He, Xiaowu Dong · 2021 · European Journal of Medicinal Chemistry
35. Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade
    Mikaël Roussel, Kieu-Suong Le, Clémence Granier, Francisco Llamas Gutierrez, Etienne D. Foucher, Simon Le Gallou, Céline Pangault, Luc Xerri, Vincent Launay, Thierry Lamy et al. · 2021 · Blood Advances
36. Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice
    Vandana Kalia, Yevgeniy Yuzefpolskiy, Adithya Vegaraju, Hanxi Xiao, Florian Martin Baumann, Shashank Jatav, Candice D. Church, Martin Prlic, Abhishek Jha, Paul Nghiem et al. · 2021 · Science Translational Medicine
37. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies
    Marc C. Pulanco, Anne Tranberg Madsen, Ankit Tanwar, Devin T. Corrigan, Xingxing Zang · 2023 · Cellular and Molecular Immunology
38. Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma
    Woods, David M., Ramakrishnan, Rupal, Laino, Andressa S., Berglund, Anders, Walton, Kelly, Betts, Brian C., Weber, Jeffrey S. · 2018 · Clinical Cancer Research
39. PDL1‐positive exosomes suppress antitumor immunity by inducing tumor‐specific CD8+ T cell exhaustion during metastasis
    Ji Chen, Yang Song, Feng Miao, Gang Chen, Yongjun Zhu, Ning Wu, Liewen Pang, Zhiming Chen, Xiaofeng Chen · 2021 · Cancer Science
40. Antipsychotic Drug Trifluoperazine Suppresses Colorectal Cancer by Inducing G0/G1 Arrest and Apoptosis
    Yong Xia, Chengsen Jia, Qiang Xue, Jinrui Jiang, Yao Xie, Ranran Wang, Zhiqiang Ran, Fuyan Xu, Yiwen Zhang, Tinghong Ye · 2019 · Frontiers in Pharmacology
41. Dynamic Post-Transcriptional Events Governing CD8+ T Cell Homeostasis and Effector Function
    Fiamma Salerno, Martin Turner, Monika C. Wolkers · 2020 · Trends in Immunology
42. A new strategy for immunotherapy of microsatellite‐stable (MSS) ‐type advanced colorectal cancer: Multi‐pathway combination therapy with PD ‐1/ PD‐L1 inhibitors
    Lingli Cai, Anqi Chen, Dong Tang · 2024 · Immunology
43. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors
    Lim, Ee Lyn, Cugliandolo, Fiorella M., Rosner, Dalya R., Gyori, David, Roychoudhuri, Rahul, Okkenhaug, Klaus · 2018 · JCI Insight
44. PLCγ1 promotes phase separation of T cell signaling components
    Longhui Zeng, Ivan Palaia, Anđela Šarić, Xiaolei Su · 2021 · The Journal of Cell Biology
45. Epigenetic modulation in cancer immunotherapy
    Stuart J. Gallagher, Elena Shklovskaya, Peter Hersey · 2017 · Current Opinion in Pharmacology
46. Dynamic regulation of CD28 conformation and signaling by charged lipids and ions
    Wei Yang, Weiling Pan, Shuokai Chen, Nicola Trendel, Shutan Jiang, Feng Xiao, Manman Xue, Wei Wu, Zeli Peng, Xiaoxi Li et al. · 2017 · Nature Structural & Molecular Biology
47. Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors
    Fan, Zhenzhen, Tian, Yahui, Chen, Zhipeng, Liu, Lu, Zhou, Qian, He, Jingjing, Coleman, James, Dong, Changjiang, Li, Nan, Huang, Junqi et al. · 2020 · EMBO Molecular Medicine
48. Engineered T cell extracellular vesicles displaying PD-1 boost anti-tumor immunity
    Baoqi Li, Tianliang Fang, Yuan Li, Tianyuan Xue, Zhirang Zhang, Liyan Li, Fanqiang Meng, Jinqiang Wang, Linlin Hou, Xin Liang et al. · 2022 · Nano Today
49. Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype
    Simone Borgoni, Andrea Iannello, Santina Cutrupi, Paola Allavena, Maurizio D’Incalci, Francesco Novelli, Paola Cappello · 2017 · OncoImmunology
50. Maintenance of CD4 T cell fitness through regulation of Foxo1
    Ryan H. Newton, Sharad Shrestha, Jenna M. Sullivan, Kathleen B. Yates, Ewoud Bernardus Compeer, Noga Ron‐Harel, Bruce R. Blazar, Steven J. Bensinger, W. Nicholas Haining, Michael Loran Dustin et al. · 2018 · Nature Immunology
51. Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma
    Jason Adhikaree, Julia Moreno-Vicente, Aanchal Preet Kaur, Andrew Mark Jackson, Poulam M. Patel · 2020 · Cells
52. Biomolecular condensates: Formation mechanisms, biological functions, and therapeutic targets
    Xin Niu, Lei Zhang, Yuchen Wu, Zhi Zong, Bin Wang, Jisheng Liu, Long Zhang, Fangfang Zhou · 2023 · MedComm
53. Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment
    Mengyao Wu, Yilan Zhao, Chi Zhang, Kanyi Pu · 2024 · ACS Nano
54. Co-stimulatory function in primary germinal center responses: CD40 and B7 are required on distinct antigen-presenting cells
    Masashi Watanabe, Chiharu Fujihara, Andrea J. Radtke, Y. Jeffrey Chiang, Sumeena Bhatia, Ronald N. Germain, Richard J. Hodes · 2017 · The Journal of Experimental Medicine
55. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers
    Karolina I. Woroniecka, Kristen Elizabeth Rhodin, Cosette A. Dechant, Xiuyu Cui, Pakawat Chongsathidkiet, Daniel S. Wilkinson, Jessica Waibl Polania, Luis A Sanchez-Perez, Peter Edward Fecci · 2019 · Clinical Cancer Research
56. PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation
    Shimizu, Kenji, Sugiura, Daisuke, Okazaki, Il-mi, Maruhashi, Takumi, Takegami, Yujiro, Cheng, Chaoyang, Ozaki, Soichi, Okazaki, Taku · 2020 · Molecular Cell
57. Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report
    Helen Marie McGuire, Elena Shklovskaya, Jarem J. Edwards, Paul Trevillian, Geoffrey William McCaughan, Patrick Bertolino, Catriona A. McKenzie, Ralph Gourlay, Stuart J. Gallagher, Barbara Fazekas de St Groth et al. · 2017 · Cancer Immunology Immunotherapy
58. Immune metabolism in PD-1 blockade-based cancer immunotherapy
    Alok Kumar, Kenji Chamoto · 2020 · International Immunology
59. TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation
    Jonathan D. Worboys, Katherine N. Vowell, Roseanna K. Hare, Ashley R. Ambrose, Margherita Bertuzzi, Michael A. Conner, Florence Patel, William H. Zammit, Judit Gali Moya, Khodor S. Hazime et al. · 2023 · Nature Communications
60. Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms
    Danilo Presotto, Efe Erdes, Minh Ngoc Duong, Mathilde Allard, Pierre‐Olivier Regamey, Manfredo Quadroni, Marie‐Agnès Doucey, Nathalie Rufer, Michaël Hebeisen · 2017 · Frontiers in Immunology
61. GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab
    Daiki Kato, Tomonori Yaguchi, Takashi Iwata, Yuki Katoh, Kenji Morii, Kinya Tsubota, Yoshiaki Takise, Masaki Tamiya, Haruhiko Kamada, Hiroki Akiba et al. · 2020 · eLife
62. Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy
    Jannie G. Borst, Julia Busselaar, Douwe M. T. Bosma, FERRY A. OSSENDORP · 2021 · European Journal of Immunology
63. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors
    Floris F. Dammeijer, Sai Ping Lau, Casper H.J. van Eijck, Sjoerd H. van der Burg, Joachim G.J.V. Aerts · 2017 · Cytokine & Growth Factor Reviews
64. Immunometabolism: Another Road to Sepsis and Its Therapeutic Targeting
    Vijay Kumar · 2018 · Inflammation
65. Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization
    Nai-Yun Sun, Yu‐Li Chen, Wen‐Yih Wu, Han-Wei Lin, Ying‐Cheng Chiang, Chi-Fang Chang, Yi‐Jou Tai, Heng‐Cheng Hsu, Chi‐An Chen, Wei‐Zen Sun et al. · 2019 · Cancers
66. Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints
    Kristian Michael Hargadon · 2020 · Clinical and Translational Medicine
67. PD-1: A Driver or Passenger of T Cell Exhaustion?
    Xing He, Chenqi Xu · 2020 · Molecular Cell
68. Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels
    Anne Marijne Heeren, Jossie Rotman, Anita G.M. Stam, Noëlle Pocorni, Awa A. Gassama, Sanne Samuels, Maaike C.G. Bleeker, Constantijne Helene Mom, Henry J.M.A.A. Zijlmans, Gemma G. Kenter et al. · 2019 · Journal for ImmunoTherapy of Cancer
69. Biomarkers for Immune Checkpoint Inhibitors in Melanoma
    Shigehisa Kitano, Takayuki Nakayama, Makiko Yamashita · 2018 · Frontiers in Oncology
70. Pembrolizumab for the treatment of cervical cancer
    Grégoire Marret, Édith Borcoman, Christophe Le Tourneau · 2019 · Expert Opinion on Biological Therapy
71. Antigen and checkpoint receptor engagement recalibrates T cell receptor signal strength
    Thomas A.E. Elliot, Emma K. Jennings, David A.J. Lecky, Natasha Thawait, Adriana Flores‐Langarica, Alastair Copland, Kendle M. Maslowski, David Cameron Wraith, David Bending · 2021 · Immunity
72. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer
    Iosune Baraibar, Oriol Mirallas, Nadia Saoudi Gonzalez, Javier Ros, Francesc Salvà, Josep M. Tabernero, Elena Élez · 2021 · Cancers
73. Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade
    Katharina Grabmeier‐Pfistershammer, Carmen Stecher, Markus Zettl, Sandra Rosskopf, Armin Rieger, Gerhard J. Zlabinger, Peter Steinberger · 2017 · Clinical Immunology
74. CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab
    André Kunert, Edwin A. Basak, Daan P. Hurkmans, Hayri Emrah Balcioglu, Yarne Klaver, Mandy van Brakel, Astrid A.M. Oostvogels, Cor H. J. Lamers, Sander Bins, Stijn L.W. Koolen et al. · 2019 · Journal for ImmunoTherapy of Cancer
75. Strategies to overcome drug resistance using SHP2 inhibitors
    Meng Liu, Shan Gao, Reham M. Elhassan, Xuben Hou, Hao Fang · 2021 · Acta Pharmaceutica Sinica B
76. Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors
    Xu, Xiaozheng, Masubuchi, Takeya, Cai, Qixu, Zhao, Yunlong, Hui, Enfu · 2021 · eLife
77. T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications
    Xiaoxia Chi, Shahang Luo, Peng Ye, Wei‐Lun Hwang, Jong‐Ho Cha, Xiuwen Yan, Wenhao Yang · 2023 · Frontiers in Immunology
78. Expansion of tumor-reactive CD8 + T cell clonotypes occurs in the spleen in response to immune checkpoint blockade
    Duncan M. Morgan, Brendan L. Horton, Vidit Bhandarkar, Richard Van, Teresa Dinter, Maria Zagorulya, John Christopher Love, Stefani Spranger · 2024 · Science Immunology
79. Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies
    Moo-Kon Song, Byeong-Bae Park, Jieun Uhm · 2019 · International Journal of Molecular Sciences
80. Coreceptors and TCR Signaling – the Strong and the Weak of It
    Alexander M. Mørch, Štefan Bálint, Ana Mafalda Santos, Simon J. Davis, Michael Loran Dustin · 2020 · Frontiers in Cell and Developmental Biology
81. Glycosylation of Immune Receptors in Cancer
    Ruoxuan Sun, Alyssa Min Jung Kim, Seung‐Oe Lim · 2021 · Cells
82. Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic T reg reduction and effector T cell activation
    Kim M. van Pul, Jessica C.L. Notohardjo, Marieke F. Fransen, Bas D. Koster, Anita G.M. Stam, Dafni Chondronasiou, Sinéad M. Lougheed, Joyce Bakker, Vinitha Kandiah, M. Petrousjka van den Tol et al. · 2022 · Science Immunology
83. Glycogen Synthase Kinase 3 Inactivation Compensates for the Lack of CD28 in the Priming of CD8+ Cytotoxic T-Cells: Implications for anti-PD-1 Immunotherapy
    Alison Taylor, Christopher E. Rudd · 2017 · Frontiers in Immunology
84. Combination Immunotherapy: Taking Cancer Vaccines to the Next Level
    Jeremy M. Grenier, Stephen T. Yeung, Kamal Mohan Khanna · 2018 · Frontiers in Immunology
85. How does T cell receptor clustering impact on signal transduction?
    Jesse Goyette, Daniel J. Nieves, Yuanqing Ma, Katharina Gaus · 2019 · Journal of Cell Science
86. The role of exosomal PD-L1 in tumor immunotherapy
    Jing Wang, Hao Zeng, Hongwei Zhang, Yunwei Han · 2021 · Translational Oncology
87. MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment
    Song, Nannan, Li, Peng, Song, Pingping, Li, Yintao, Zhou, Shuping, Su, Qinghong, Li, Xiaofan, Yu, Yong, Li, Pengfei, Feng, Meng et al. · 2020 · Frontiers in Cell and Developmental Biology
88. Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial
    Manuel Jorge Rodrigues, Giulia Vanoni, Pierre Loap, Coraline Dubot, Eleonora Timperi, Mathieu Minsat, Louis Bazire, Catherine Durdux, Virginie Fourchotte, Enora Laas et al. · 2023 · Nature Communications
89. Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
    Xinyu Yan, Shouyue Zhang, Yun Deng, Peiqi Wang, Qianqian Hou, Heng Xu · 2018 · Frontiers in Pharmacology
90. Novel therapeutic strategies for spinal osteosarcomas
    M. Akhtar Anwar, Chirine El‐Baba, Muhammed H. Elnaggar, Yasmeen O. Elkholy, Mohamed Mottawea, Dina Johar, Tuqa S. Al Shehabi, Firas H. Kobeissy, Charbel K. Moussalem, Elie Massaad et al. · 2019 · Seminars in Cancer Biology
91. The tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells
    Hongcheng Cheng, Kaili Ma, Lianjun Zhang, Guideng Li · 2021 · Cancer Letters
92. Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma
    Julia Peña-Asensio, H. Calvo, M. Torralba, J. Miquel, E. Sanz-de-Villalobos, J. Larrubia · 2021 · Cancers
93. Molecular Mechanisms Governing CD8 T Cell Differentiation and Checkpoint Inhibitor Response in Cancer
    Lisa Rausch, Axel Kallies · 2025 · Annual Review of Immunology
94. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy
    Angela Rita Elia, Matteo Grioni, Veronica Basso, Flavio Curnis, Massimo Freschi, Angelo Corti, Anna Mondino, Matteo Bellone · 2018 · Clinical Cancer Research
95. SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling
    Charlène Niogret, W. Birchmeier, G. Guarda · 2019 · Frontiers in Immunology
96. Re-defining T-Cell Exhaustion: Subset, Function, and Regulation
    Se Jin Im, Sang‐Jun Ha · 2020 · Immune Network
97. The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade
    Isobel Okoye, Lai Xu, John W. T. Walker, Shokrollah Elahi · 2020 · Cancer Immunology Immunotherapy
98. PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
    Christopher D. Zahm, Jena E. Moseman, Lauren E. Delmastro, Douglas G. Mcneel · 2021 · OncoImmunology
99. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
    Hao, Huai-Xiang, Wang, Hongyun, Liu, Chen, Kovats, Steven, Velazquez, Roberto, Lu, Hengyu, Pant, Bhavesh, Shirley, Matthew, Meyer, Matthew J., Pu, Minying et al. · 2019 · Molecular Cancer Therapeutics
100. FOXP3+ regulatory T cells and the immune escape in solid tumours
     Yiran Qiu, Shouyu Ke, Jieqiong Chen, Zhizhen Qin, Wenle Zhang, Yaqin Yuan, Dehua Meng, Gang Zhao, Kejin Wu, Bin Li et al. · 2022 · Frontiers in Immunology